Anika Therapeutics (ANIK) Non-Current Deffered Revenue (2010 - 2016)

Anika Therapeutics (ANIK) has 7 years of Non-Current Deffered Revenue data on file, last reported at $48000.0 in Q4 2016.

• On a quarterly basis, Non-Current Deffered Revenue fell 27.27% year-over-year to $48000.0 in Q4 2016; TTM through Dec 2016 was $48000.0, a 27.27% decrease from a year earlier, with the FY2016 full-year figure at $48000.0, down 27.27% from the prior year.
• Non-Current Deffered Revenue for Q4 2016 stood at $48000.0, down from $59000.0 in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for ANIK reached as high as $4.3 million in Q1 2012 and fell as low as $48000.0 in Q4 2016.
• Historically, Non-Current Deffered Revenue has averaged $1.1 million across 5 years, with a median of $79940.5 in 2015.
• Across the five-year window, Non-Current Deffered Revenue sank 97.21% in 2014 and jumped 30.74% in 2015, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $2.2 million in 2012, then decreased by 4.54% to $2.1 million in 2013, then slumped by 95.04% to $102000.0 in 2014, then tumbled by 35.29% to $66000.0 in 2015, then dropped by 27.27% to $48000.0 in 2016.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $48000.0 in Q4 2016, $59000.0 in Q3 2016, and $56000.0 in Q2 2016.